文献速递其他结缔组织病

泛PPAR激动剂IVA337在实验性肺纤维化及肺动脉高压中有效

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
PubMed 文献 · Ann Rheum Dis · 2017-08-11

该研究在博来霉素诱导的肺纤维化小鼠模型和Fra-2转基因小鼠(非特异性间质性肺炎伴严重肺血管重塑导致肺动脉高压)中评估泛过氧化物酶体增殖物激活受体(PPAR)激动剂IVA337的抗纤维化作用。每日口服灌胃30 mg/kg或100 mg/kg IVA337或溶媒至4周,结果显示100 mg/kg IVA337可显著减轻两种模型的肺纤维化并改善Fra-2小鼠的肺动脉高压。

要点

  • 100 mg/kg IVA337使博来霉素模型组织学评分降低61%,Fra-2模型降低50%。
  • 100 mg/kg IVA337使肺羟脯氨酸含量分别降低28%和48%。
  • IVA337改善Fra-2小鼠血流动力学及血管重塑,减轻肺动脉高压。

核心结论

  • 100 mg/kg IVA337可预防两种互补动物模型的肺纤维化,并显著减轻Fra-2小鼠模型的肺动脉高压。
  • 泛PPAR激动剂IVA337是这些心肺受累的潜在治疗候选药物。

研究设计与样本

  • 在博来霉素诱导肺纤维化小鼠模型和Fra-2转基因小鼠模型中进行临床前研究。
  • 小鼠每日口服灌胃IVA337 30 mg/kg或100 mg/kg或溶媒,最长4周。

主要发现

  • 与溶媒组相比,100 mg/kg IVA337使博来霉素模型组织学评分降低61%,Fra-2模型降低50%。
  • 与溶媒组相比,100 mg/kg IVA337使肺羟脯氨酸浓度分别降低28%和48%。
  • 100 mg/kg IVA337显著降低两种模型病变肺中纤维化标志物水平。
  • 100 mg/kg IVA337通过改善血流动力学测量和血管重塑,显著减轻Fra-2小鼠的肺动脉高压。
  • 在原代人肺成纤维细胞中,IVA337剂量依赖性抑制TGF-β诱导的成纤维细胞向肌成纤维细胞转化及PDGF介导的成纤维细胞增殖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the antifibrotic effects of the pan-peroxisome proliferator-activated receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and related pulmonary hypertension (PH). METHODS: IVA337 has been evaluated in the mouse model of bleomycin-induced pulmonary fibrosis and in Fra-2 transgenic mice, this latter being characterised by non-specific interstitial pneumonia and severe vascular remodelling of pulmonary arteries leading to PH. Mice received two doses of IVA337 (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks. RESULTS: IVA337 demonstrated at a dose of 100 mg/kg a marked protection from the development of lung fibrosis in both mouse models compared with mice receiving 30 mg/kg of IVA337 or vehicle. Histological score was markedly reduced by 61% in the bleomycin model and by 50% in Fra-2 transgenic mice, and total lung hydroxyproline concentrations decreased by 28% and 48%, respectively, as compared with vehicle-treated mice. IVA337 at 100 mg/kg also significantly decreased levels of fibrogenic markers in lesional lungs of both mouse models. In addition, IVA337 substantially alleviated PH in Fra-2 transgenic mice by improving haemodynamic measurements and vascular remodelling. In primary human lung fibroblasts, IVA337 inhibited in a dose-dependent manner fibroblast to myofibroblasts transition induced by TGF-β and fibroblast proliferation mediated by PDGF. CONCLUSION: We demonstrate that treatment with 100 mg/kg IVA337 prevents lung fibrosis in two complementary animal models and substantially attenuates PH in the Fra-2 mouse model. These findings confirm that the pan-PPAR agonist IVA337 is an appealing therapeutic candidate for these cardiopulmonary involvements.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Avouac J, Konstantinova I, Guignabert C, et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017. PMID: 28801346. doi:10.1136/annrheumdis-2016-210821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。